Cytochromes P450 (P450) 2B6 and 3A5 are inactivated by bergamottin (BG). P450 2B6 metabolized BG primarily to M3 and M4 and one minor metabolite (M1). The metabolites were analyzed, and the data indicated that M1 was bergaptol, M3 was 5Ј-OH-BG, and M4 was a mixture of 6Ј-and 7Ј-OH-BG. Because 6Ј-and 7Ј-OH-BG were the primary metabolites, it suggested that P450 2B6 preferentially oxidized the geranyloxy chain of BG. Metabolism of BG by P450 3A5 resulted in three major metabolites: [bergaptol, M3 (5Ј-OH-BG), and M5 (2Ј-OH-BG)], and two minor metabolites [M2 (6Ј,7Ј-dihydroxy-BG) and M4 (6Ј-and 7Ј-OH-BG)]. Because bergaptol was the most abundant metabolite formed, it suggested that P450 3A5 metabolized BG mainly by cleaving the geranyl-oxy chain. Molecular modeling studies confirmed that docking of BG in the P450 2B6 active site favors oxidation in the terminal region of the geranyl-oxy chain, whereas positioning the 2Ј-carbon of BG nearest the heme iron is preferred by P450 3A5. Glutathione (GSH)-BG conjugates were formed by both P450. Each enzyme predominantly formed conjugates with m/z values of 662. Tandem mass spectrometry analysis of the GSH conjugates indicated that the oxidation forming a reactive intermediate occurred on the furan moiety of BG, presumably through the initial formation of an epoxide at the furan double bond. The data indicate that oxidation of the geranyl-oxy chain resulted in the formation of stable metabolites of BG, whereas oxidation of the furan ring produced reactive intermediates that may be responsible for binding to and inactivating P450 2B6 and 3A4.The polymorphic cytochromes P450 (P450) 3A5 and 2B6 are involved in the metabolism of many clinically important drugs used in chemotherapy, hormone therapy, suppression of immune responses, or as inhibitors of human immunodeficiency virus proteases (Ingelman-Sundberg, 2004). P450 3A5 is found primarily in liver, intestine, and lung and shares 85% amino acid sequence homology with the major human drug-metabolizing enzyme P450 3A4 (Wrighton et al., 1990;Ding and Kaminsky, 2003). The P450 3A family of enzymes is involved in the metabolism of at least 60% of drugs that are currently in clinical use (Wrighton et al., 1990). Recent reports indicate important clinical consequences for individuals expressing the polymorphic P450 3A5 in the metabolism of immune suppressants and statins (Hesselink et al